International Journal of Medical and Pharmaceutical Research
2025, Volume-6, Issue-4 : 485-490 doi: 10.5281/zenodo.16789968
Original Article
Prospective comparitive study between Ecospirin and Rivoraxaban in prevention of DVT in post TKR patients
 ,
 ,
 ,
 ,
 ,
 ,
Published
Aug. 10, 2025
Abstract

Introduction: The risk of postoperative venous thromboembolism (VTE) is higher for patients having total knee arthroplasty (TKA) or total hip arthroplasty (THA).One of the main causes of post-operative morbidity and mortality is VTE, which includes both pulmonary embolism (PE) and deep vein thrombosis (DVT). Up to 40–60% of post-operative patients may develop DVT and 1-2 percent may die from PE, if proper prophylaxis is not take.According to current standards, prophylactic treatment should be administered for at least 10–14 days and should be seriously considered for up to 35 days

Objectives of study: To compare the effect of Ecospirin and Rivoroxan  in prevention of DVT in post TKR patients

Materials and methods: Patient who underwent TKR  in BGSGIMS  during a period of 2 yrs ( from December 2022 – December 2024 ) were given Ecospirin/ Rivaroxaban pre and post  operativly were observed for the signs of DVT for a given period  and compared the effects of both drugs during the period

Results: This is a hospital-based study. The trial duration was two years, from December 2022 to December 2024.The study comprised a total of 30 patients. Of these, 20 were females and 10 were males. Out of 30 patients no one developed VTE or PE . There was no significant difference in incidance of  PE and VTE between ecospirin and rivoroxaban groups

Conclusion: In our study out of 30 patients 18 patients were given ecospirin and 12 were given rivoroxaban . Pre operatevly and post operatevily assesed using Knee society score. Effect of ecosipirin and rivoroxaban is analysed. There is no statistically difference in incidance of DVT and PE . The limitations of our study includes it is a hospital based study , only limited patients are assessed and it doesn’t conclude the whole population

Recommended Articles
Loading Image...
Volume-6, Issue-4
Citations
2614 Views
277 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved